Metotrexato Pfizer

Methotrexate, the active ingredient in Metotrexato Pfizer, is an antimetabolite presented as a sterile solution for intramuscular, intravenous and intrathecal use. It is employed to treat autoimmune disorders and certain malignancies in adult and pediatric patients. GNH USA supplies Metotrexato Pfizer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across several disease families, chiefly autoimmune conditions and hematologic malignancies. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation, improving plaque severity. - Acute lymphoblastic leukemia: interferes with leukemic cell replication, supporting remission. - Non‑Hodgkin lymphoma: impedes tumor growth as part of combination chemotherapy. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting: mild to moderate gastrointestinal upset. - Fatigue: general tiredness or reduced energy. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects: - Bone marrow suppression: pancytopenia requiring close monitoring. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe hepatotoxicity: fibrosis or cirrhosis with prolonged use. - Renal impairment: acute kidney injury from precipitation of drug crystals.

Methotrexate therapy requires careful monitoring and specific safety measures. - Monitor blood counts: perform regular CBC to detect marrow suppression. - Assess liver function: schedule periodic LFTs to identify hepatotoxicity. - Avoid in pregnancy: contraindicated due to teratogenic risk; ensure effective contraception. - Adjust for renal impairment: dose reduction or alternative therapy may be needed. - Counsel on folic acid supplementation: reduces mucosal and hematologic toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several drug classes that can modify its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate serum levels and risk of toxicity. - Proton pump inhibitors: may reduce renal clearance, heightening adverse effects.

Moderate Interactions (Monitor Closely): - Penicillins and other β‑lactam antibiotics: can potentiate bone marrow suppression. - Sulfonamides: may enhance hematologic toxicity. - Live vaccines: immunosuppression can diminish vaccine efficacy and increase infection risk.